Mortality due to tumour lysis syndrome · children with haematological malignancy at risk of tumour lysis syndrome
1 finding from 1 review
Function · patients with osteoarthritis of the knee
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Health‐related quality of life measures Participant opinion: improvement · patients with osteoarthritis of the knee
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · patients with osteoarthritis of the knee
It is very uncertain whether closing wedge high tibial osteotomy (CW‐HTO) changes adverse events compared with unicompartmental knee arthroplasty (very low certainty).
1 finding from 1 review
All‐cause mortality · patients with osteoarthritis of the knee
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Reoperation rate · patients with osteoarthritis of the knee
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Treatment failure rate · patients with osteoarthritis of the knee
It is very uncertain whether closing wedge high tibial osteotomy (CW‐HTO) changes treatment failure rate compared with unicompartmental knee arthroplasty (very low certainty).
1 finding from 1 review
Pain · patients with osteoarthritis of the knee
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Restoration survival · Permanent posterior teeth with single-surface cavities
The pooled survival rate was 93% at 2 years.
6 findings from 1 review
Show 3 more findings
Restoration survival · Permanent posterior teeth with multiple-surface cavities
The pooled survival rate was 41% at 2 years.
3 findings from 1 review
Survival percentage 41 [18, 67]
1 study
GRADE not reported
Survival percentage 86 [59, 98]
3 studies
GRADE not reported
Survival percentage 77 [56, 92]
1 study
GRADE not reported
Restoration survival · Primary posterior teeth with single-surface cavities
The pooled survival rate was 95% at 1 year.
3 findings from 1 review
Restoration survival · Primary posterior teeth with multiple-surface cavities
The pooled survival rate was 62% at 2 years.
3 findings from 1 review
Leaving the study early: insufficient response ‐ When compared with ultra low dose (<2 mg/day) · patients with schizophrenia
HIGH DOSE (greater than or equal to 10 mg/day) probably leads to lower leaving the study early: insufficient response ‐ When compared with… compared with ANY DOSE ‐ short term (moderate certainty).
1 finding from 1 review
Leaving the study early: insufficient response ‐ When compared with low dose (greater than or equal to 2‐<4 mg/day) · patients with schizophrenia
HIGH DOSE (greater than or equal to 10 mg/day) probably leads to lower leaving the study early: insufficient response ‐ When compared with… compared with ANY DOSE ‐ short term (moderate certainty).
1 finding from 1 review
Leaving the study early: insufficient response ‐ When compared with standard‐lower dose (greater than or equal to 4‐<6 mg/day) · patients with schizophrenia
HIGH DOSE (greater than or equal to 10 mg/day) showed no clear difference in leaving the study early: insufficient response ‐ When compared with… compared with ANY DOSE ‐ short term (moderate certainty).
1 finding from 1 review
Global state: 1. No clinically important improvement ‐ CGI‐I ‐ when compared with low dose (greater than or equal to 2‐<4 mg/day) · patients with schizophrenia
HIGH DOSE (greater than or equal to 10 mg/day) probably leads to lower global state: 1. No clinically important improvement ‐ CGI‐I ‐ when… compared with ANY DOSE ‐ short term (moderate certainty).
1 finding from 1 review
Mental state: 1. No clinically important improvement ‐ as measured by PANSS ‐ when compared with standard‐low dose (greater than or equal to 4‐<6 mg/day) · patients with schizophrenia
HIGH DOSE (greater than or equal to 10 mg/day) showed no clear difference in mental state: 1. No clinically important improvement ‐ PANSS ‐ when… compared with ANY DOSE ‐ short term (moderate certainty).
1 finding from 1 review
Adverse effects: 6. Movement disorders ‐ specific symptoms ‐ EPS: unspecified ‐ versus low dose (greater than or equal to 2‐<4 mg/day) · patients with schizophrenia
HIGH DOSE (greater than or equal to 10 mg/day) probably leads to higher adverse effects: EPS: unspecified ‐ when compared with low dose… compared with ANY DOSE ‐ short term (moderate certainty).
1 finding from 1 review
Number of participants with ≥ 75% reduction in all seizures · Lennox‐Gastaut syndrome, any age
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
50% or greater reduction in seizure frequency · Lennox‐Gastaut syndrome, any age
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found